Trial Profile
A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms IDIOME-STUDY
- 04 Feb 2024 The trial has been discontinued in Italy.
- 14 Dec 2021 Interim results of a Phase 2 study (Idiome) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 16 Mar 2021 Planned End Date changed from 15 Jan 2024 to 2 Apr 2025.